Core Viewpoint - Hong Kong-listed Huajian Medical experienced a recovery in share price after a significant drop of over 10% in the morning session, following the announcement of a strategic partnership with Renhe Pharmaceutical's wholly-owned subsidiary, Renhe International, to establish the world's first vertical RWA exchange focused on the OTC (over-the-counter) drug sector in the United States [1] Group 1 - Huajian Medical's share price fell more than 10% in the morning session before turning positive in the afternoon [1] - The company announced a strategic cooperation with Renhe International to develop a vertical RWA exchange for OTC drugs in the U.S. [1] - This partnership aims to create a dedicated platform for the OTC drug market, indicating a significant move within the pharmaceutical industry [1]

Group 1 - The company has announced a strategic partnership with Renhe Pharmaceutical's wholly-owned subsidiary, Renhe International, to establish the world's first vertical RWA exchange focused on the OTC (over-the-counter) drug sector in the United States [1]